|Podcasts|June 25, 2018

Episode 11: From Field to Boardroom with Former NFL Star Solomon Wilcots

Former NFL star and current sports broadcaster, Solomon Wilcots talks about the intersection of sports and biopharma. He discusses traumatic brain injuries and whether or not the NFL is doing enough about it, projects he has been working on that match professional athletes who are passionate about a certain disease with biopharma companies, and how lessons from the football field can be applied to the boardroom.

Former NFL star and current sports broadcaster, Solomon Wilcots talks about the intersection of sports and biopharma. He discusses traumatic brain injuries and whether or not the NFL is doing enough about it, projects he has been working on that match professional athletes who are passionate about a certain disease with biopharma companies, and how lessons from the football field can be applied to the boardroom.

You can listen and/or download the episode on SoundCloud, or directly through iTunes, GooglePlay, Stitcher, and Overcast.

 

 

 


Related to this article

Pharmaceutical Executive Daily
FDA reportedly shelves its Commissioner’s National Priority Voucher program, Eli Lilly breaks ground on a $3.5 billion Pennsylvania manufacturing site for next-generation obesity treatments, and Parexel’s Stacy Hurt on how small protocol decisions can become enrollment and retention barriers.
Pharmaceutical Executive Daily
FDA approves Merck KGaA’s Pimjetmi for tenosynovial giant cell tumor, Parexel’s Stacy Hurt on when patient input should enter the clinical research process, and Ignite Proteomics’ Dr. Brian Corgiat on adjusting for tumor mutations in treatment decisions.
Pharmaceutical Executive daily
argenx acquires Unnatural Products for up to $1.15 billion to expand its immunology capabilities, GiftHealth’s Chip Parkinson on how single-partner platforms can transform the prescription journey, and Partha Anbil on why competing on net value matters more than cutting list prices as US drug pricing resets.